Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease and proposes potential treatment pathway with sonlicromanol

Ads

You May Also Like

Endologix Completes Patient Enrollment in the Ovation® LIFE (Least Invasive Fast-Track EVAR) Study

IRVINE, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer ...

Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, ...